Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Felis Catus (cat hair allergen) is a biological extract used as a diagnostic and bronchoprovocation challenge agent in clinical research. In studies conducted by the University of North Carolina, Chapel Hill, the extract is administered via inhalation to individuals with allergic asthma to identify those who exhibit a late-phase asthmatic response (LPAR). This physiological response, which occurs several hours after the initial IgE-mediated mast cell degranulation, is used to phenotype patients for inclusion in trials testing novel asthma therapies, such as IL-1β inhibitors. The extract contains the major allergen Fel d 1, which cross-links allergen-specific IgE on mast cells and basophils, triggering the release of inflammatory mediators and inducing airway obstruction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Felis Catus.